INTRODUCTION
Gastric adenocarcinoma is a health problem worldwide due to its high incidence and mortality rates, being the fourth most common malignancy and the second leading cause of cancer death [1] . Its prognosis is highly dependent on the stage at diagnosis but usually presents at an advanced stage requiring demanding treatments and costs and impairing quality of life (QoL), even for patients with a good prognosis [2] .
In health economics studies, the clinical strategies adopted for a problem such as gastric cancer are compared by simultaneously addressing their di erences in terms of both clinical bene ts and the cost of achieving them [3] . Guidelines recommend conducting cost-utility analysis where the use of clinical bene ts should be adjusted to patient preferences. us, life-years saved (LYS) may be adjusted to utilities in terms of QoL, quality adjusted life years (QALYs), meaning that 1 year of life is multiplied by a utility factor between 1 and 0, providing di erent values for each single year of life, resulting in an utility value that will vary between 1 QALY (one year with perfect J Gastrointestin Liver Dis, December 2014 Vol. 23 No 4: 371-378 QoL) and 0 (death, by de nition). ese guidelines also suggest that community preferences should be used instead of patient preferences [4] [5] [6] .
In a recent systematic review of the literature on economic studies relating to gastric cancer our group found that authors mostly used patient preferences instead of the recommended community preferences and that utilities were obtained by using several measurement instruments, including questionnaires that were speci cally created for comparing gastric cancer treatments that should not be compared to utilities in the general population. Also, models tend to use utilities reported in other studies, usually conducted in countries di erent from the population in the model, where health valuations might have given di erent results [7] . Utilities obtained in a population with a single questionnaire could be very suitable for conducting cost-utility analysis on the gastric cancer problem since they would provide comparative utilities for all stages of the gastric cancer cascade from an asymptomatic population to gastric cancer patients [8] .
us, the aim of our study was to perform a cross-sectional study to obtain utilities from a population that would include patients without gastric lesions and also with all kinds of upper gastrointestinal diseases, including patients with all ranges of gastric premalignant conditions, patients submitted to endoscopic treatments and patients with gastric cancer submitted to all available treatments [9] [10] [11] .
METHODS
is cross-sectional study was performed in 8 Portuguese hospitals over 6 months, between 2012 and 2013, by delivering a QoL related questionnaire to patients already scheduled for routine upper gastrointestinal endoscopic examinations. e questionnaire was the Portuguese version of the EQ-5D-5L and the reference test for the diagnosis was the gastroenterology diagnosis, including the histopathology result when applicable. The planning, development and report of the study are in accordance with the STROBE statement for reports on observational studies [12, 13] .
Portugal is considered to have a high-incidence of gastric cancer according to the GLOBOCAN de nition by presenting an age-standardized incidence rate of 13.7 per 100,000 [14] . From all over the country, including north, centre, south of Portugal and the two major cities of Lisbon and Porto, 8 gastroenterology departments in 8 di erent hospitals comprising 2 academic hospitals, 3 oncology centers and 3 regional hospitals, were invited and agreed to participate. Consecutive patients were included in each hospital for 3 months and each patient scheduled for an upper endoscopy procedure was invited to complete a questionnaire before the examination to self-report their QoL on the day of the examination. e outcomes obtained were the self-reported answers to the questionnaire, providing a measure of QoL on the day of the upper endoscopy procedure, plus the diagnosis provided by the attending gastroenterologist, which can be based on the endoscopic diagnosis, pathology result or known medical history, as applicable. To allow for generalization of results, a selection of hospitals was made in order to obtain a heterogeneous population in terms of both geographic location and hospital setting.
e only inclusion criteria were the completion of an already scheduled upper endoscopy along with a voluntary signed informed consent speci c to the study. Exclusion criteria were emergency examinations, failure to provide informed consent or any contraindication for upper endoscopy.
e study was approved by the Portuguese Data Protection Authority (Authorization 4982/2012) a er granting permission for the compilation of multicenter national data, and also by each hospital Ethics Committee. Con dentiality of all records was ensured by removing the names of patients, doctors and nurses from the reports before they were sent to the main investigator.
Selection bias was minimized by asking all institutions for a consecutive sample, having a very broad inclusion criteria setting and carrying out the study in the whole country in hospitals with very di erent population characteristics, for at least 3 months in order to allow the inclusion of most types of upper gastrointestinal diseases.
QoL questionnaire
The questionnaire used was the EQ-5D-5L developed by the EuroQol Group, which is a standardized measure to provide utilities for clinical and economic appraisal [15] . is questionnaire was chosen because it can be applied to a wide range of health conditions and treatments, provides a simple descriptive pro le and a single index value for each health status, has been validated over many years in a number of populations and settings, is the most recent version of the EuroQol EQ-5D questionnaire and is available in several translations, including an already validated and reliable Portuguese version [16] .
The EQ-5D-5L questionnaire comprises a descriptive system and a visual analogue scale (VAS). e descriptive system has 5 dimensions: mobility, self care, usual activities, pain/discomfort and anxiety/depression, and each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems (the former EQ-5D had only 3 choices per question, being called EQ-5D-3L). Respondents are asked to indicate their health state by marking the box against the most appropriate statement in each of the 5 dimensions. e digits for the 5 dimensions can be combined in a 5-digit number describing the respondent's health state. Health states de ned by the EQ-5D-5L descriptive system were converted into a single index value to calculate utilities, according to the recommendations of the EuroQol Group [17] .
e similar EQ-5D-3L system was only recently validated in the Portuguese population, by setting preferences for the general population using the time trade-o technique and also developing population norms [18, 19] . Because currently there is no validated method to transform utilities from the EQ-5D-3L to the EQ-5D-5L systems, we used the Spanish EQ-5D-5L utilities. From the available options, the Spanish utilities are the most similar, providing a Pearson's correlation coe cient of r=0.946 for both EQ-5D-3L population norms [18] .
e VAS records the respondent's self-rated health on a 20 cm vertical VAS, with endpoints labeled "the best health you can imagine" and "the worst health you can imagine". A correctly completed questionnaire was de ned as a questionnaire with each of the 5 multiple choice questions for the descriptive system completed with a single cross and a clear and readable number in the VAS.
Endoscopic procedure
For each questionnaire the corresponding diagnosis was obtained from the upper endoscopy result. Upper endoscopy is considered the ideal procedure for the diagnosis of upper gastrointestinal diseases due to its widespread availability, improved accuracy for most diseases, relatively minor invasiveness and possibility of performing diagnostic and/ or therapeutic procedures [20] [21] [22] [23] [24] . ere were no speci c inclusion or exclusion criteria based on patient diagnosis, endoscopists' experience, type of endoscopic facility or scope. Biopsies were done as deemed necessary, but not speci cally for participation in the study.
Sample size and statistical analysis
For the sample size calculation, an estimate of at least 44 patients per group would be needed for a level of signi cance of 0.05 and a power of 0.80, based on previous reports that for normal patients the utility score was 0.90, for patients with premalignant conditions 0.70 and for patients with gastric cancer 0.50. We aimed at obtaining 100 patients for each of these groups, to ensure that con dence intervals would not be wider than ±0.10, in order to achieve statistically signi cant di erences between utilities [25] .
Results are reported as means and 95% con dence interval (CI) for continuous variables and percentages for proportions. For comparative analysis the Student's t-test was used for continuous variables according to their normal distribution and the Pearson chi-square test for dichotomous variables. A two-sided p value <0.05 was considered to be statistically signi cant. Results were analyzed in subgroups for confounding factors such as age or gender but not for co-morbidities. No data was missing from the retrieved questionnaires.
RESULTS
All subjects scheduled for an upper endoscopy were invited and a er exclusions for several factors such as refusing to Table I . Participants were 53% male with a mean age of 59 years. e examination was considered normal in only 24% of cases, and most relevant abnormalities detected were gastric premalignant conditions such as gastritis, atrophy or intestinal metaplasia and esophageal conditions such as hiatal hernia or esophagitis. There were no relevant differences between participating institutions in terms of patients' diseases, except for there being more cancer patients in the Oncology Centers, as expected (13.7% vs. 4.7%, p=0.01).
In terms of the 5 dimensions of the EQ-5D-5L questionnaire, 75% to 93% of participants said they had no or only slight problems in all ve dimensions with better score for self-care such as washing or dressing themselves and only 2.2% to 6.1% reported severe to extreme problems with worst score for usual activities such as work, study, housework, family or leisure. Anxiety was moderate to extreme in 21% of patients without relevant di erences among groups (no lesions 21%, premalignant conditions 23%, gastric cancer 18%).
Although the numbers of included questionnaires vary and are related to a diverse prevalence of these diseases in the general population, VAS scores were consistently lower than the EQ-5D-5L utilities, regardless of organ or severity of disease, in all conditions analyzed.
Utilities for all stages of the gastric cancer cascade of carcinogenesis, with subgroup analysis by gender and including only patients aged 50 or over are summarized in Table II. is subgroup analysis is justi ed by the fact that this is the population (≥50 years) which is usually considered to be coste ective to o er endoscopic screening or surveillance strategies [26] . No comparison between <50 and ≥50 years was made due to the huge di erences between groups in terms of available questionnaires 371 vs. 1063 and gastric cancer cases 11 vs. 137.
Overall scores demonstrated that the two scales provided similar results for patients without gastric lesions or with gastric premalignant conditions with utilities lower for patients who had present gastric cancer than for patients without gastric lesions or those with premalignant conditions (0.68 versus ≥0.77, p=0.09).
When adjusting for gender and including only patients aged 50 or above, the results consistently show that utilities were lower for women than for men. is dissimilar scoring for males and females achieves a statistically signi cant di erence in some normal or premalignant conditions in both scales.
DISCUSSION
is cross-sectional study of patients scheduled for an upper endoscopy procedure provided utilities and selfreported QoL data for a nationwide population with a validated questionnaire in a sample of patients embracing all stages of the carcinogenic cascade for gastric adenocarcinoma. ese results, although speci c to the studied population, might be relevant to further cost-utility studies in gastric cancer as a recent systematic review showed that utilities were relevant in several studies for the nal results of the economic analysis, namely QoL in diseased patients and also a er treatments for cancer [7, 8] .
Utilities measured by the EQ-5D-5L questionnaire showed similar scores for patients without gastric lesions (0.78), patients with premalignant conditions (0.82) and patients with previously treated gastric cancer (0.77-0.79) but lower values for patients with present carcinoma (0.66) and for the same clinical situations the EQ-5D-5L scores were always lower for female than for male.
To the best of our knowledge this study is the first providing utilities for all stages of the gastric cancer cascade using a single health utilities measurement instrument. e study provides very useful information for authors conducting cost-utility analysis by incorporating utilities in their Markov models [8] .
Our main conclusion and contribution to the actual medical practice is that the use of a single standardized instrument like EQ-5D-5L for all stages of disease is feasible, that it captures differences among stages (no lesions vs. premalignant conditions vs. present cancer) and adjustments by gender are relevant when incorporating utilities in economic models.
A second relevant conclusion is that the utilities varied between di erent stages of disease in a much narrower set of values (around 0.6 for cancer vs. 0.8 for no cancer) than previously reported in other models (around 0.3 vs. 0.9 for the same groups), raising the concern that utilities valuation by using di erent questionnaires for di erent stages of disease, as has been done in other models, might overvalue real di erences and overestimate the nal economic conclusions among strategies. Advantages of this study is that it includes patients on a nationwide basis, from general and teaching hospitals, and oncology centers, it covers more than 1400 reports, providing more than 100 patients in each subgroup (no lesions vs. premalignant lesions vs. gastric cancer) and utilities are linked to a medical diagnosis con rmed by a doctor a er performing an endoscopy with biopsies when needed. In addition, by including a range of upper gastrointestinal diseases it means that utilities of the general population with the same background are comparable.
To prevent selection bias as possible, a variety of hospitals from all over the country were selected, participants were consecutive and unselected, no change in routine practice was necessary and the analysis of the results was blinded. Also, anxiety caused by endoscopy that could in uence the results in terms of utilities was consistently similar among groups.
When comparing our study results to the study by Gold et al used for the sample size calculation, utilities values in other diseases returned similar results to ours: for esophageal problems 0.70 vs. 0.69 and for peptic ulcer 0.66 vs. 0.62. Also, in a study performed in our country using the same EQ-5D questionnaire in gastrointestinal patients (n=125), utilities for gastric cancer (n=5) ranged between 50 and 70, including our result of 0.62 [27] .
e nding of di erent utilities between male and female is in accordance with a similar study in Portugal and also in other countries, con rming that this consistent result should be incorporated in cost-utility models [19, 28] .
e relevance of the present study to the already available literature comes from the existence of several problems within the methodology of cost-utility studies published. We think these problems might have been overcome with the present study (see Table III We think that it is very important to use a single validated instrument for all stages of disease so that utilities among di erent stages are not overestimated by the use of di erent and not comparable questionnaires. Also, as suggested by the guidelines, utilities valuation should come from community preferences as ours did and not only from diseased patients [4] .
The results of our study have implications on the interpretation of previous models on endoscopic surveillance of gastric premalignant conditions because the wider utilities' values used by others could result from using different questionnaires for different clinical situations, thereby overestimating di erences in utilities and the nal model outcome between strategies.
is study has some limitations that need to be addressed: in one hospital the questionnaires were completed after performing upper endoscopy while in all the others this was done before the examination and, although it is expected that answers to items such as mobility, self-care, usual activities and pain or discomfort are not in uenced by the examination, the item on anxiety might be in uenced by whether the questionnaire was completed before or a er the endoscopy. Also, in the absence of standard health values for the Portuguese population for the validated questionnaire used (EQ-5D-5L) we used values for the Spanish population. Although the populations are di erent and their valuation of QoL will be dissimilar, the closest possible proximity and geographic location should provide some degree of similarity.
CONCLUSIONS
Our results con rm the applicability of using a single standardized instrument such as EQ-5D-5L for all stages of disease as it captures di erences in utilities among stages and gender and wider di erences among stages reported in previous models might result from the use of di erent instruments and overestimate real dissimilarities. ese conclusions may be relevant to further cost-utility analysis in gastric cancer and should be incorporated by authors in their models.
